Eli Lilly and Innovent agree Verzenios commercialisation deal in China
Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer.
Drug Development
Anixa Biosciences secures Korean patent for breast cancer vaccine
Zymeworks agrees to buy Theravance Biopharma for $929m
FDA issues complete response letter to Sobi’s NASP for gout
Lilly’s Jaypirca receives CHMP positive opinion for CLL in Europe
Immunai and Boehringer partner to identify T-cell targets
Ionis grants Recordati rights to zilganersen for Alexander disease
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
